View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Amrep Corp: 1 director

A director at Amrep Corp sold 13,000 shares at 31.558USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

 PRESS RELEASE

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-...

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points SAN DIEGO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company (“BioAtla” or the “Company”) focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it has entered into definitive agreements with certain institutional investors for the issuance and sale of 9,679,158 shares of its common stock in a registered direct offering. Each...

 PRESS RELEASE

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinic...

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting Improved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) as compared to Mec-V treated patient with treatment-refractory NSCLC expressing wild-type KRAS (wtKRAS) One-year OS was 58% for patients with NSCLC expressing mKRAS versus 23% for wtKRAS Mec-V antit...

 PRESS RELEASE

AMREP Reports Second Quarter Fiscal 2025 Results

AMREP Reports Second Quarter Fiscal 2025 Results HAVERTOWN, Pa., Dec. 13, 2024 (GLOBE NEWSWIRE) -- AMREP Corporation (NYSE:AXR) today reported net income of $4,042,000, or $0.75 per diluted share, for its 2025 fiscal second quarter ended October 31, 2024 compared to net income of $1,108,000, or $0.21 per diluted share, for the same period of the prior year. For the first six months of 2025, AMREP had net income of $8,106,000, or $1.51 per diluted share, compared to net income of $2,454,000, or $0.46 per diluted share, for the same period of 2024. Revenues were $11,906,000 and $30,997,000 ...

 PRESS RELEASE

BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot T...

BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming International Association for the Study of Lung Cancer (IASLC) 2024 Hot Topic in Basic & Translational Science Meeting to be held in Washington, DC from December 13–15, 2024. Prese...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

BioAtla Reports Third Quarter 2024 Financial Results and Highlights Re...

BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 trial in squamous cell carcinoma of the head and neck (SCCHN) continues to demonstrate durable clinical responses and median overall survival (OS) of approximately 9 months (ongoing) in a heavily pretreated population; actionable feedback received from the U.S. Food and Drug Administration (the “FDA”) regarding our proposed pivotal trial in second-line (2L) plus SCCHNEvalstotug (CAB-CTLA-4) in combination with PD-1 demonstrates tumor reduction in all eight, first-li...

 PRESS RELEASE

BioAtla to Announce Third Quarter 2024 Financial Results and Provide B...

BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024 SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, November 7, 2024 at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2024 and provide business highlights. Conference Cal...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: October 19, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: October 16, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: October 12, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

LUV SOUTHWEST AIRLINES CO.
TTSH TILE SHOP HOLDINGS INC.
MOFG MIDWESTONE FINANCIAL GROUP
MEI METHODE ELECTRONICS INC.
KVHI KVH INDUSTRIES INC.
GDOT GREEN DOT CORPORATION CLASS A
CTRN CITI TRENDS INC.
CRMT AMERICA'S CAR-MART INC.
CODI COMPASS DIVERSIFIED HOLDINGS
CDXS CODEXIS
AHH ARMADA HOFFLER PROPERTIES INC.
NEWT NEWTEK BUSINESS SERVICES INC.
A0JMXQ INDIA CAPITAL GROWTH FUND LTD.
RLMD RELMADA THERAPEUTICS
CULP CULP INC.
EBF ENNIS
APTV APTIV PLC
NANX NANOPHASE TECHNOLOGIES CORP.
AXR AMREP
ETON ETON PHARMACEUTICALS
STIM STIMSONITE CORP
INMB INMUNE BIO
NFE INC.
CAPR NEW FORTRESS ENERGY
EPSN CAPRICOR THERAPEUTICS
FBIO EPSILON ENERGY LIMITED
WSC FABIEN CORP
VRDN WILLSCOT MOBILE MINI HOLDINGS CORP
CTLP VIRIDIAN THERAPEUTICS INC
SMMT CANTALOUPE
PFBX INC.
BMEA SUMMIT THERAPEUTICS INC
FTHY PEOPLES FINANCIAL CORP. (MISSISSIPPI)
ASLE BIOMEA FUSION
BHVN INC.
BIGZ FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND
BUKS AERSALE CORP
ECBK BIOHAVEN LTD
CDIO BLACKROCK INNOVATION AND GROWTH TST
GRNT BUTLER NATIONAL CORP
GTE ECB BANCORP INC.
CRBP CARDIO DIAGNOSTICS HLDGS INC
BMEZ GRANITE RIDGE RESOURCES INC
ASGI GRAN TIERRA ENERGY INC.
SYRS CORBUS PHARMACEUTICALS HOLDINGS INC.
PEO BLACKROCK HEALTH SCIENCES TERM TRUST
XPER ABERDEEN STANDARD GLOBAL INFRASTRUCTURE INCOME FUND
OMIC SYROS PHARMACEUTICALS INC.
PMN PETROLEUM & RESOURCES CORPORATION
BNTC XPERI INC
CLNN SINGULAR GENOMICS SYSTEMS INC
BNZI PROMIS NEUROSCIENCES INC.
SIRI BENITEC BIOPHARMA INC
CLENE INC
BANZAI INTERNATIONAL INC
SIRIUS XM HLDGS INC NEW
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: October 11, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: October 10, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: October 8, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: October 5, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: October 4, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

BioAtla Announces Upcoming Poster Presentation at the 39th Society for...

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held from November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX. Presentation Details: Titl...

 PRESS RELEASE

BioAtla Announces Upcoming Oral Presentation at the Society for Melano...

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced acceptance of an abstract for oral presentation at the upcoming Society for Melanoma Research 21st International Congress (SMR), being held from October 10–13, 2024, in New Orleans, LA. Oral Presentation Details: Abstract...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: September 28, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: September 24, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch